Avant Technologies and Ainnova in Talks to Obtain Innovative Technology in Preventative Health Reporting
LAS VEGAS, May 20, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the companies are in talks with an international healthcare innovation company to license or potentially acquire its patented early disease detection technology. If successful, it's a global license or acquisition that has the potential to revolutionize preventive health reporting and to generate correlations for future detection of new diseases without the need for all the patient's data.
Avant and Ainnova continue to grow the footprint and capabilities of their technology portfolio with the goal of being a leader in early disease detection using the Company's signature AIdriven Vision AI technology platform.
Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said of the Company's aim to continue to add to its portfolio, "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily. We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem.
"To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions."
Avant and Ainnova see the retina as a new vital sign, but also understand that leveraging the results of laboratory tests and basic patient data can all work in concert to provide a comprehensive health report.
Vargas added, "We have already integrated an exclusive license for four algorithms into our Vision AI platform, and we are now in talks to license and potentially acquire an innovative technology that would be a game changer in our industry."
Avant will inform its shareholders of any updates at an appropriate time.
About Ainnova Tech, Inc.Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies, Inc. Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:https://twitter.com/AvantTechAI https://www.linkedin.com/company/avant-technologies-ai https://www.facebook.com/AvantTechAIhttps://www.youtube.com/@AvantTechAI
Forward-Looking StatementsCertain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:Avant Technologies, Inc.info@avanttechnologies.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/avant-technologies-and-ainnova-in-talks-to-obtain-innovative-technology-in-preventative-health-reporting-302460374.html
SOURCE Avant Technologies Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/20/c0445.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight
MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2025 MedTech Innovation Spotlight on Friday, June 13, 2025. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at About Inspire Medical SystemsInspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. For additional information about Inspire, please visit Investor and Media ContactEzgi YagciVice President, Investor Relationsezgiyagci@ in to access your portfolio
Yahoo
21 minutes ago
- Yahoo
How To Earn $500 A Month From Campbell's Stock Ahead Of Q3 Earnings
Campbell's Company (NASDAQ:CPB) will release its third-quarter earnings results before the opening bell on Monday, June 2. Analysts expect the Camden, New Jersey-based company to report quarterly earnings at 66 cents per share, down from 75 cents per share in the year-ago period. Campbell's projects to report quarterly revenue of $2.43 billion. Compare that to the $2.37 billion it reported last year, according to data from Benzinga Pro. On May 23, Piper Sandler analyst Michael Lavery maintained Campbell's with an Overweight rating and lowered the price target from $45 to $42. With the recent buzz around Campbell's, some investors may be eyeing potential gains from the company's dividends too. As of now, Campbell's offers an annual dividend yield of 4.57%, which is a quarterly dividend amount of 39 cents per share ($1.56 a year). So, how can investors exploit its dividend yield to pocket a regular $500 monthly? To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $131,418 or around 3,846 shares. For a more modest $100 per month or $1,200 per year, you would need $26,277 or around 769 shares. To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($1.56 in this case). So, $6,000 / $1.56 = 3,846 ($500 per month), and $1,200 / $1.56 = 769 shares ($100 per month). View more earnings on CPB Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time. How that works: The dividend yield is computed by dividing the annual dividend payment by the stock's current price. For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40). Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield. CPB Price Action: Shares of Campbell's gained 1.1% to close at $34.17 on More: Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? THE CAMPBELL'S (CPB): Free Stock Analysis Report This article How To Earn $500 A Month From Campbell's Stock Ahead Of Q3 Earnings originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Pasofino Gold Announces Its Attendance at the Mining Investment Event in Quebec City, Quebec from June 3-5, 2025
Toronto, Ontario--(Newsfile Corp. - May 30, 2025) - Pasofino Gold Limited (TSXV: VEIN) (OTCQB: EFRGF) (FSE: N07A) ("Pasofino" or the "Company") is pleased to announce that it will be in attendance for the Mining Investment Event taking place in Quebec City, Quebec, from June 3rd to June 5th 2025, inclusive. Chief Executive Officer, Mr. Brett Richards, commented: "We are looking forward to the Mining Investment Event this coming week in Quebec City, and welcome Issuers and investors interested in hearing the new Pasofino Gold story, and its path to production." ABOUT THE DUGBE GOLD PROJECT The 2,078 km2 Dugbe Gold Project (the "Project") is in southern Liberia and situated within the southwestern corner of the Birimian Supergroup which is host to most West African gold deposits. To date, two deposits have been identified on the Project; Dugbe F and Tuzon discovered by Hummingbird in 2009 and 2011 respectively. The deposits are located within 4 km of the Dugbe Shear Zone which is thought to have played a role in large scale gold mineralization in the area. A significant amount of exploration in the area was conducted by Hummingbird up until 2012 including 74,497 m of diamond coring. Pasofino drilled an additional 14,584 m at Tuzon and Dugbe during 2021. These deposits have a combined Mineral Resource Estimates dated 17 November 2021 with total Measured and Indicated of 3.3 Moz with an average grade of 1.37 g/t Au, and 0.6 Moz in Inferred. Following the completion of the Definitive Feasibility Study in June 2022 a Mineral Reserve Estimate was declared, based on the open-pit mining of both deposits over a 14-year Life of Mine. A technical report for the Dugbe Gold Project was prepared in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects ("NI 43-101") and filed on SEDAR+ at and on the Company's website. In addition to the existing deposits there are many gold prospects within the Project including the Bukon Jedeh area and the DSZ target on the Tuzon-Sackor trend where Pasofino has discovered a broad zone of surface gold mineralisation in trench and outcrop along strike from Tuzon. At this and several of the other prospects no drilling has been carried out to date. In 2019, Hummingbird signed a 25-year Mineral Development Agreement ("MDA") with the Government of Liberia providing the necessary long-term framework and stabilization of taxes and duties. Under the terms of the MDA, the royalty rate on gold production is 3%, the income tax rate payable is 25% (with credit given for historic exploration expenditures), the fuel duty is reduced by 50%, and the Government of Liberia is granted a free carried interest of 10% in the Project. QUALIFIED PERSONS STATEMENT Scientific or technical information in this disclosure that relates to exploration results was prepared and approved by Mr. Andrew Pedley. Mr. Pedley is a consultant of Pasofino Gold Ltd.'s wholly-owned subsidiary ARX Resources Limited. He is a member in good standing with the South African Council for Natural Scientific Professions (SACNASP) and is as a Qualified Person under NI 43-101. ABOUT PASOFINO GOLD LTD. Pasofino Gold Limited is a Canadian-based mineral exploration company listed on the TSX Venture Exchange (VEIN). Pasofino, through its wholly-owned subsidiary, owns 100% of the Dugbe Gold Project (prior to the issuance of the Government of Liberia's 10% carried interest). For further information, please visit or contact: Brett A. RichardsChief Executive Officer & DirectorT: +1 905 449 1500E: brett@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS This news release contains "forward-looking statements" that are based on expectations, estimates, projections and interpretations as at the date of this news release. Forward-looking statements are frequently characterised by words such as "plan", "expect", "project", "seek", "intend", "believe", "anticipate", "estimate", "suggest", "indicate" and other similar words or statements that certain events or conditions "may" or "will" occur, and include, without limitation, statements regarding the ability to raise the funds to finance its ongoing business activities including the acquisition of mineral projects and the exploration and development of its projects. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such risks and other factors may include, but are not limited to, risks related to investor engagement and interest, the results of business operation, the ability to advance the Dugbe Gold Project, the results of exploration activities; the results of the strategic review process, the ability of the Company to complete further exploration activities; timing and availability of external financing on acceptable terms and those risk factors outlined in the Company's Management Discussion and Analysis as filed on SEDAR+. The Company does not undertake to update any forward-looking information except in accordance with applicable securities laws. NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES To view the source version of this press release, please visit
